

## Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

Agnés Fournier · Franco Berrino ·  
Françoise Clavel-Chapelon

Published online: 26 July 2007  
© Springer Science+Business Media B.V. 2007

**Erratum to: Breast Cancer Res Treat**  
**DOI: 10.1007/s10549-007-9523-x**

Unfortunately a Table 1 with errors was published in the article. Please find here the corrected data.

---

The online version of the original article can be found under  
doi: [10.1007/s10549-007-9523-x](https://doi.org/10.1007/s10549-007-9523-x)

---

A. Fournier · F. Clavel-Chapelon (✉)  
Institut National de la Santé et de la Recherche Médicale ERI 20,  
Institut Gustave Roussy, 94805 Villejuif, France  
e-mail: [clavel@igr.fr](mailto:clavel@igr.fr)

F. Berrino  
Department of Preventive and Predictive Medicine, Istituto  
Nazionale Tumori, 20138 Milan, Italy

**Table 1** Selected baseline characteristics of participants overall and according to whether or not they had used HRT as recorded at the end of follow-up

	All ( <i>n</i> = 80,377) <i>n</i> (%) or mean (SD)	HRT never-users ( <i>n</i> = 23,703) <i>n</i> (%) or mean (SD)	HRT ever-users ( <i>n</i> = 56,674) <i>n</i> (%) or mean (SD)
Year of birth			
[1925–1930[	6,617 (8.2%)	4,003 (16.9%)	2,614 (4.6%)
[1930–1935[	11,066 (13.8%)	4,601 (19.4%)	6,465 (11.4%)
[1935–1940[	16,377 (20.4%)	4,052 (17.1%)	12,325 (21.7%)
[1940–1945[	20,673 (25.7%)	3,960 (16.7%)	16,713 (29.5%)
≥1945	25,644 (31.9%)	7,087 (29.9%)	18,557 (32.7%)
Age at start of follow-up, years	53.1 (4.5)	55.0 (4.8)	52.3 (4.1)
Age at menarche, years			
<13	37,498 (46.7%)	11,116 (46.9%)	26,382 (46.6%)
≥13	42,879 (53.3%)	12,587 (53.1%)	30,292 (53.4%)
Parity			
Nulliparous	9,747 (12.1%)	3,400 (14.3%)	6,347 (11.2%)
Parous, first child before 30, 1 or 2 children	39,892 (49.6%)	10,615 (44.8%)	29,277 (51.7%)
Parous, first child before 30, 3+ children	22,594 (28.1%)	7,071 (29.8%)	15,523 (27.4%)
Parous, first child after 30	8,144 (10.1%)	2,617 (11.0%)	5,527 (9.8%)
Breastfeeding, months <sup>a</sup>			
Never	20,682 (29.3%)	5,711 (28.1%)	14,971 (29.7%)
<12	38,539 (54.6%)	10,178 (50.1%)	28,361 (56.4%)
≥12	3,906 (5.5%)	1,549 (7.6%)	2,357 (4.7%)
Unknown	7,503 (10.6%)	2,865 (14.1%)	4,638 (9.2%)
Age at menopause, years	50.2 (3.7)	50.7 (3.9)	50.1 (3.6)
Type of menopause			
Artificial	6,611 (8.2%)	1,831 (7.7%)	4,780 (8.4%)
Natural/Unknown	73,766 (91.8%)	21,872 (92.3%)	51,894 (91.6%)
Personal history of benign breast disease			
Yes	21,259 (26.4%)	5,561 (23.5%)	15,698 (27.7%)
No	59,118 (73.6%)	18,142 (76.5%)	40,976 (72.3%)
Family history of breast cancer in first degree relatives			
Yes	9,256 (11.5%)	2,970 (12.5%)	6,286 (11.1%)
No	71,121 (88.5%)	20,733 (87.5%)	50,388 (88.9%)
Body Mass Index, kg/m <sup>2</sup>			
≤ 20	11,231 (13.4%)	2,697 (11.4%)	8,534 (15.1%)
]20–25]	50,912 (63.3%)	13,382 (56.5%)	37,530 (66.2%)
]25–30]	14,649 (18.2%)	5,730 (24.2%)	8,919 (15.7%)
>30	3,585 (4.5%)	1,894 (8.0%)	1,691 (3.0%)
Total physical activity, MET-h/wk <sup>b</sup>			
<34	19,536 (24.3%)	5,984 (25.2%)	13,552 (23.9%)
[34–47[	20,935 (26.1%)	5,868 (24.8%)	15,067 (26.6%)
[47–62[	19,957 (24.8%)	5,818 (24.5%)	14,139 (24.9%)
≥62	19,949 (24.8%)	6,033 (25.5%)	13,916 (24.6%)

<sup>a</sup> Among parous women<sup>b</sup> Metabolic equivalent cost-hour/week